A strong start to the week for the AIM All Share, with the market trading sideways throughout. With Wall Street closed for Labor Day, distractions have been limited with the junior index closing up more than four points at 768.64.
- ImmuPharma +105%
- N4 Pharma +35%
- Versarien +25%
- Wishbone -16%
- Empyrean -15%
ImmuPharma LON:IMM topped the board, adding 105%. The company made two statements this morning, having completed new patent applications and also in the wake of making senior appointments. These moves are seen as key in terms of commercialising the product portfolio.
- AIM Market Roundup: ImmuPharma, Rockfire Resources, Likewise
- AIM Market Roundup: Dewhurst, Metir, Tertiary Minerals
N4 Pharma LON:N4P was 35% higher, but there’s no news out. Trade was lumpy and the closing spread was around 10%. There is an alignment with the work done by Immupharma here but is this more than just read across/
- AIM Market Roundup: N4 Pharma, Future Metals, Star Energy
- N4 Pharma achieves proof of targeted RNA delivery in lung cancer cells
Versarien LON:VRS is on the list again, today up 25%. The share price has been volatile through a tightly managed refinancing which is again looking like a close call. An update on Friday hammered the share price – this is just a partial recovery.
- AIM Market Roundup: Tomco Energy, Versarien, Mindflair
- AIM Market Roundup: Oracle Power, Versarien, EnergyPathways
Wishbone LON:WSBN was the biggest faller, down 16%. The company last week announced a funding round with new shares set to be admitted tomorrow. That decline does however come off the back of a significant rally for the stock.
- AIM Market Roundup: Wishbone, Nativo Resources, Arecor Therapeutics
- AIM Market Roundup: Wishbone, Geo Exploration, Empire Metals
Empyrean LON:EME was 15% lower with a mid-session release of final results unsettling sentiment. It’s been a challenging year and unwinding operations in Indonesia appears to be dragging. Further funding will be necessary in the next year based on the latest cashflow forecasts.
